Text
Led by Professor Glenn King of Infensa Bioscience and involving a nationwide team of researchers, the $17.8 million, Medical Research Future Fund-backed human clinical trials for the drug are slated for 2025. This exciting breakthrough could become the world’s first drug to limit heart cell death during oxygen deprivation –expanding donor heart availability and improving survival rates—by turning spider venom into a lifesaving innovation.
